Puma Biotechnology (PBYI) - Quarterly EPS earnings growth

Brandmark of Puma Biotechnology Inc (PBYI)

Puma Biotechnology (PBYI) relies on the effective delegation of production to contract partners to ensure supply stability. The integration of AI into molecular screening accelerates the discovery of new drugs, although clinical tests remain the responsibility of physicians. Analyzing this quarterly EPS chart, where the latest value is recorded as -34.80, the company's pricing power is evident due to the uniqueness of the drug Nerlynx in breast cancer therapy.

Puma Biotechnology, Inc. (PBYI) - Earnings per share growth in annualized terms for the last twelve months from 07/04/2022 to 11/10/2026

Analytical breakdowns for Puma Biotechnology (PBYI)

- market value and analyst target forecast:
Price Chart pumabiotechnology.com|PBYI - Broker Consensus Forecast
- market capitalization indicators:
Market Capitalization Puma Biotechnology Inc|PBYI - Real Price to Acquire Entire Company
- balance sheet net asset value indicators:
Book Value per Share Puma Biotechnology|PBYI - Total Stockholders' Equity|Market Value to Book Value Ratio pumabiotechnology.com|PBYI - Aggregate Asset Value
- debt and liquidity details:
Debt to Equity Puma Biotechnology|PBYI - Long-Term Liabilities to Equity|Short-Term Debt to Equity Ratio pumabiotechnology.com|PBYI - Company Aggregate Debts|Debt to Book Capitalization Ratio Puma Biotechnology Inc|PBYI - Company Long-Term Liabilities|Company Short-Term Debts Puma Biotechnology|Quick Liquidity Indicator pumabiotechnology.com
- earnings and valuation multiples indicators:
PBYI - Final Profit|Projected Future Earnings Puma Biotechnology|PBYI - Price to Earnings Ratio|Forward P/E Multiple pumabiotechnology.com|PBYI - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Puma Biotechnology Inc|PBYI - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Puma Biotechnology|PBYI - Earnings per share for the last four quarters|Quarterly EPS earnings growth pumabiotechnology.com|PBYI - Earnings per share growth rate in current year|Earnings growth forecast for next year Puma Biotechnology
Initial company analysis:Puma Biotechnology
Manufactured product of Puma Biotechnology, Inc.

Puma Biotechnology possesses effective operating leverage due to the outsourcing of Nerlynx production. A mathematical calculation of the daily change in earnings per share within the quarterly EPS history allows for the filtering of random market noise. This metric measures the actual resilience of business margins against rising costs. Steady growth in this indicator confirms the direct conversion of sales into net profit. Overpaying for an asset during a period of inflation risks freezing capital.

Main competitors

Olema (OLMA) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months GLSI|ZNTL (Zentalis Pharmaceuticals Inc) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months MacroGenics Inc. (MGNX)|Quarterly EPS earnings growth PSTV|PCSA - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Eagle Pharmaceuticals, Inc. EGRX